
DERM Stock Forecast & Price Target
DERM Analyst Ratings
Bulls say
Journey Medical is supported by a commercial ramp in Emrosi that is already demonstrating strong underlying demand, with 3Q26 revenue of $19.0M, Emrosi sales of $9.0M, and prescriptions up 98.6% year over year while unique prescribers topped 5,000 and refill rates rose about 12% quarter over quarter. The bullish case is strengthened by improving access, including the largest U.S. national health plan covering 25M+ lives beginning in January 2027, which should lift quality coverage and convert signed formulary wins into reimbursed volume. Financially, gross margin expanded to 69%, adjusted EBITDA reached $3.5M, and EBITDA was positive for a second straight quarter, showing the business can scale profitably as coverage broadens.
Bears say
Journey Medical is facing a weak fundamental setup because its key dermatology products appear vulnerable to slower-than-expected adoption, competitive branded generics, and payer pressure, with 3Q26 prescriptions already declining 0.7% sequentially for Qbrexza and 12.9% for Accutane. The company’s outlook is further pressured by regulatory and patent uncertainty, since pipeline success does not ensure FDA approval and an unfavorable Qbrexza litigation outcome could allow Perrigo to launch a generic earlier than projected. Financially, lower revenue expectations have already led to 2026 EPS being cut to $(0.29) from $(0.06) and 2027 EPS to $0.15 from $1.07, while the need for additional capital could also dilute shareholders.
This aggregate rating is based on analysts' research of Journey Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
DERM Analyst Forecast & Price Prediction
Start investing in DERM
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Journey Medical Corp (DERM) Forecast
DERM Analyst Forecast & Price Prediction
Start investing in DERM
Order type
Buy in
Order amount
Est. shares
0 shares